Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Cited by 21 Publications

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	M1;qc2NmdGxiVnnhZoltcXS7IFHzd4F6	MY[wMVAvPSEQvF2=	MVyyOEBp		NHXNPVdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	Mo\WNlU3PjN5Nkm=
HepG2-HBV1.1	NF36NZlCeG:ydH;zbZMhSXO\|YYm=	NGHlN5oxNTBwNTFOwG0>	MYmyOEBp		MWLpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	MlzKNlU3PjN5Nkm=
HepG2.2.15	NInHXWxHfW6ldHnvckBCe3OjeR?=	M2KwOFAvOSEQvF2=	NWLaUG94OjRiaB?=		NXraZ4g3eHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v	NF30blYzPTZ4M{e2PS=>
HepG2-HBV1.1	NGrnPZJHfW6ldHnvckBCe3OjeR?=	MVWwMlEh\|ryP	NVrmeHZUOjRiaB?=		NYP6emRYeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v	MUKyOVY3Ozd4OR?=
HepG2-HBV1.1	NVnCXJFtTnWwY4Tpc44hSXO\|YYm=	NWjuN49vOC5zIN88US=>	MWi0PEBp		Mn[4dJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW\|IFThcoUheGG{dHnjcIV{	NHrQZ5YzPTZ4M{e2PS=>
HepG2-HBV1.1	NXrm[\|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof2NE4yKM7:TR?=	NHTpU\|kyNTViZB?=		MWDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	M3fYZlI2PjZ\|N{[5
HepG2-HBV1.1	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCwMlEh\|ryP	MWixMVUh\A>?		Mnv4bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?=	MlW0NlU3PjN5Nkm=
HepG2-HBV1.1	NVzVflV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi4NE4yKM7:TR?=	MWCxNk04OiCq		MoPUbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDheEBUNXCqYYPl	M371PFI2PjZ\|N{[5
HepG2-HBV1.1	NX3Gcmh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q1W\|AvOSEQvF2=	MWKxNk04OiCq		NEXuVIVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	MYWyOVY3Ozd4OR?=
Raji	MlXmSpVv[3Srb36gRZN{[Xl?	NXnINGppOC53wrFOwG0>	MUC3NkBp		MkK2ZYJwdGm\|aHXzJIF2fG:yaHHnfeKh	NVHubJRUOjV2NE[zO\|c>
SK-MEL-28	M1[3PWZ2dmO2aX;uJGF{e2G7	NWHyO2hvOzBibl2=	NGP4Onk3KGh?		MVTpcoR2[2W\|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>?	NH61[GEzPTNzM{CxNC=>
H157	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFOy[3NKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?=	NHH0fZozPTJ3N{mxNS=>
Jurkat	M3vQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rPWVEuOyCwTR?=	MWm0POKhcA>?	MoLmSG1UVw>?	NUTrfm5y\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	M2rjXlI2OTV4MUS2
CEM	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInWdmYyNTNibl2=	MVy0POKhcA>?	MkDQSG1UVw>?	Monn[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NWrQT5lLOjVzNU[xOFY>
P12	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjWc\|JlOS1\|IH7N	NGS0[2Y1QMLiaB?=	NFPDNlhFVVOR	M1HmfIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	MWCyOVE2PjF2Nh?=
KB	NIPibolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3PZ\|FKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN	NEfKPW4zPTB3OEWyOi=>
KBv200 (ABCB1)	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPWTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?=	M13zWFI2ODV6NUK2
SUDHL6	M{jMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1G4T\|HjiIoQvF2=	NFuzXFI1QC95MjDo		M4fX[olvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	NXPqPVlVOjR7NkG2NFQ>
SUDHL6	MVLGeY5kfGmxbjDBd5NigQ>?	MoPYNgKBkc7:TR?=	MWC3NkBp		NVzlfopkcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W\|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?=	M{\OSFI1QTZzNkC0
HCT-116	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS3S2k2OD13IH7N	NWXveZlROjR7Mke4OVc>
SKNBe2C	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTN{LklCtVQvOCCwTR?=	NVjFOo9MOjR7MkG5NlA>
IGNR91	NXzrb4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PGN2lEPTB;MkSuN:KyOS55IH7N	NYDxUpB{OjR7MkG5NlA>
SKNAS	NG\ZR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vuNWlEPTB;MT61xtExNjJibl2=	NUPxVWlzOjR7MkG5NlA>
LAN1	NHT6cIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;lWZdtUUN3ME2yMlPDuTBwMjDuUS=>	NVm0NGJyOjR7MkG5NlA>
SHSY5Y	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HJVWlEPTB;OD6yxtExNjZibl2=	NFi1bFUzPDl{MUmyNC=>
A549-WT	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF7LkSzO{DDuSByLkW5OEAhdk1?	NVPTenVmOjR6NUi4Nlc>
A549-R	NUXMU2J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrOZXZIUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N	MY[yOFg2QDh{Nx?=
MCF-7-WT	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3xdo92UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N	MX6yOFg2QDh{Nx?=
MCF-7-R	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>?	MmHiNlQ5PTh6Mke=
A549-R	NHLLUVVEgXSxdH;4bYNqfHliQYPzZZk>				MX7JR\|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>?	MX2yOFg2QDh{Nx?=
MCF-7-R	NEO2fXVEgXSxdH;4bYNqfHliQYPzZZk>				NE\2foVKSzVyPUWuOVM6KMLzIECuNVQ1KG6P	NUPWVmY3OjR6NUi4Nlc>
SW620	M1Hybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTdwOECgxtEhOC5yODDuUS=>	M3HQTlI1PzJ4N{O5
SW620/AD300	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFryXJpKSzVyPUmwPU43OCEEsTC4MlkyKG6P	NIfZWmozPDd{NkezPS=>
HEK293/pcDNA3.1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwNEWgxtEhOC5{MDDuUS=>	MVKyOFczPjd\|OR?=
HEK293/ABCC1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXexO4RKUUN3ME2xPU4zQSEEsTCyMlA5KG6P	M3rydlI1PzJ4N{O5
TCC	M2XiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF;3eWYzPCCq		NGfzWoFKSzVyPUewJI5O	NYH6XnZnOjR5MU[5OFQ>
TCC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlfMOFghcA>?		M4\wPWlEPTB;NUCgcm0>	MnLCNlQ4OTZ7NES=
HepG2/ADM	NGnWbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwN{i2N:KyOC5{M{exJO69VQ>?	Mk\LNlQ4ODR3NU[=
HepG2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfWTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1?	MmqzNlQ4ODR3NU[=
MCF-7/ADR	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLxSmpKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?=	MlvKNlQ4ODR3NU[=
MCF-7	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULM[W1ZUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2=	MWmyOFcxPDV3Nh?=
A-172	M13mR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjOSGdyOC5zwrFOwG0>	M1H5PVI1Nzd{IHi=		MV\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	Mo\vNlQ2OzB{M{W=
U-251MG	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HtUlAvOcLizszN	NG\vVIEzPC95MjDo		MUXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NETGcZYzPDV\|MEKzOS=>
DLD-1	Moi0SpVv[3Srb36gRZN{[Xl?	NEHvdI4yODBibl2=	MoXrOFghcA>?		MlO4dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	M2qwNlI1PDB\|NEWz
CCD18Co	NWnsZllUTnWwY4Tpc44hSXO\|YYm=	M1\Vd\|ExOCCwTR?=	MlXhOFghcA>?		NYS3SYxVeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi	MkOzNlQ1ODN2NUO=
DLD-1	NVjvdI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULSOVUxOC1zMECwJI5O	Ml7JOFghcA>?		MnLobY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NWTvbllEOjR2MEO0OVM>
CCD18Co	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXy0[2xyOC1zMECwJI5O	NHXUNFI1QCCq		MnT5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4LKc\|I1PDB\|NEWz
HepG2	NHvtb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3H4NVI1KGh?		M1radGlEPTB;NUKuOgKBkc7:TR?=	M4TCTlI1OzRzNki4
HEK293/pcDNA3.1	NVuwUHRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMEC0xtExNjByMEOg{txO	MViyOFI5PDd6Mx?=
HEK293/MRP1	NHq2cJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K2emlEPTB;MD6wOVXDuTBwMEGyNEDPxE1?	MoXnNlQzQDR5OEO=
Ramos	M1rMUGFxd3C2b4Ppd{BCe3OjeR?=	MnLsNwKBkc7:TR?=	MUm0PEBp		M4HRUYlv\HWlZYOgN\|QvPiYEsUGuPVImKGGyb4D0c5Nqew>?	MlXuNlQzPTZ2OUG=
NCI-H1299/pcDNA3	NHXhSYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHm5e2MxNTJyIH7N	M1HTOFk3KGh?		M3XBNIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MmSzNlQyPzdyMUK=
H1299/ICAM-3	NFLmXXpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NG\6Z4QxNTJyIH7N	MXy5OkBp		MmnTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	M{L2dlI1OTd5MEGy
NCI-H1299/pcDNA3	MXnGeY5kfGmxbjDBd5NigQ>?	MmDpNU82NzFyL{KwxsBvVQ>?	M{e1d\|k3KGh?		NIf2VVdqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR	MUSyOFE4PzBzMh?=
H1299/ICAM-3	NIr3OYNHfW6ldHnvckBCe3OjeR?=	NGfO[nQyNzVxMUCvNlDDqG6P	NV;DTY46QTZiaB?=		M3XpPYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA>	NGT0UFYzPDF5N{CxNi=>
W1	M2DEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j6emlEPTB;MD6wNFMzKM7:TR?=	M{fPflI1OTRyMUe2
W1VR	NU\4RpViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXUNGxKSzVyPUCuNFU3KM7:TR?=	M1PWNVI1OTRyMUe2
K562	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwMEOyJOKyKDBwMECxJEDPxE1?	NVfLW2pNOjRzM{W5N\|c>
K562/ADR	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>?	NELNe5EzPDF\|NUmzOy=>
K562	NX7PTnVpSXCxcITvd4l{KEG\|c3H5	MWOwMlMh\|ryP	MVOyOEBp		M4DFOYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	MnG0NlQyOzV7M{e=
K562/ADR	MXHBdI9xfG:\|aYOgRZN{[Xl?	M3LOSVMh\|ryP	MXqyOEBp		M4LyU4lv\HWlZYOgZZBweHSxc3nz	NH34WnMzPDF\|NUmzOy=>
A549	NYXiT4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\MfZg2UUN3ME2wMlExKMLzIECuNFMh\|ryP	MmTzNlM6PzFyN{W=
K562	Ml7UR4VtdCCYaXHibYxqfHliQYPzZZk>	MVizMlc26oDVNkFCpI5O	M1TwV\|czyqCqwrC=		NWrpT2o1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	MViyN\|g4PzJ{Mx?=
lucena	M135cmNmdGxiVnnhZoltcXS7IFHzd4F6	MlniN{44PeLCk{[wxsBvVQ>?	MmXaO\|LDqGkEoB?=		NU[xWZVrdm9iZX\m[YN1	M1H1dFI{QDd5MkKz
FEPS	M4HodWNmdGxiVnnhZoltcXS7IFHzd4F6	MkP2N{44PeLCk{[wxsBvVQ>?	MmToO\|LDqGkEoB?=		Mn30co8h\W[oZXP0	NXzkd3RkOjN6N{eyNlM>
A2780	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPVSFRiUUN3ME2zMlUhdU1?	MnHYNlM5Ojl{MEO=
ACHN	NXjMbJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTZTWM2ODxyLkGgcW0>	M2LOT\|I{QDJ7MkCz
U-937	NUL1PJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vXTmlEPTB:M{Sgcm0>	MmjNNlM5Ojl{MEO=
Jurkat	M2jwcWFxd3C2b4Ppd{BCe3OjeR?=	MlrZOeKh\|rypL33sxsA>	MV[yOEBp		NYHWbZlXcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NXnGXIFzOjN6MUC0NFk>
Jurkat	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK4ZZY2yqEQvHevcYzDqA>?	M{\Nc\|I1KGh?		MkPXZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn	NW\UW44xOjN6MUC0NFk>
Hep-2	M4q3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwMEVCtVAvODFizszN	NHLL[o4zOzd6MESyOC=>
Hep-2/v	M17uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml23TWM2OD1zLklCtVAvOjBizszN	M33NeVI{PzhyNEK0
SGC-7901	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfkNE0yOCEQvHevcYw>	NH;hUXozPC92OD:3NkBp		MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NXvoe4l{OjN5NEO1O\|I>
SGC-7901/VCR	M3yyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf3dIQxNTFyIN88[{9udA>?	NHm1RoEzPC92OD:3NkBp		MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MXqyN\|c1OzV5Mh?=
SGC-7901	MoP1RZBweHSxc3nzJGF{e2G7				MlTCbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	MkeyNlM4PDN3N{K=
SGC-7901/VCR	NUPaRlZpSXCxcITvd4l{KEG\|c3H5				MWnpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NIHhbmYzOzd2M{W3Ni=>
KB-3-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3jO2tKSzVyPUGuOlYhyrFiMD6xOlIh\|ryP	MnrTNlM3PzN2NEW=
KB-C2	NGXxXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJyMj61OkDDuSB2Mj60PFEh\|ryP	NYHyVVFzOjN4N{O0OFU>
KB-3-1	NXzCOY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfPToFKSzVyPUGuNlYhyrFiMD6wNlch\|ryP	MWeyN\|Y4OzR2NR?=
KB-V1	NIL5WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHnfVlKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?=	MXqyN\|Y4OzR2NR?=
HEK293/pcDNA3.1	NFuwPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYj2c2VbUUN3ME2yOE4yKMLzIECuNlA1KM7:TR?=	Ml;qNlM3PzN2NEW=
HEK293/ABCB1	M2\SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\K[GlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN	Mom5NlM3PzN2NEW=
A549/EGFP	M12zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTiNE4xOS1zMECwJO69VQ>?			MXfJR\|UxRTh4LkegxtEhOjlwMTFOwG0>	MVOyN\|Y{PDJ6Mh?=
A549/Slug	NIrqZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3VOWMxNjBzLUGwNFAh\|ryP			NGHaS4VKSzVyPUmuO{DDuSB\|LkGg{txO	NWDPXI9kOjN4M{SyPFI>
JFCR39	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXqNUDDvU1?	NG\TNVczPCCq	MUnEUXNQ	MXTtZZJs\WSueTDpcoNz\WG\|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{	MV2yN\|U6QDJ5Nh?=
A549	NWTGXJlzTnWwY4Tpc44hSXO\|YYm=	MVGxNFAhdk1?	MorCNVYhcA>?	M1ficmROW09?	NEnje5Rt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW\|	M2LEe\|I{PTl6Mke2
SGC7901	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTFwMkdihKnDueLCiUCuNVEh\|rypL33s	NV\o[ld6OjN3NkS0PFI>
SGC7901/LV-NC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLI[VQyUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>?	NGjvXXAzOzV4NES4Ni=>
SGC7901/LV-SGO1	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfYNlZvUUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>?	MUSyN\|U3PDR6Mh?=
SGC7901/VCR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrydWlKSzV\|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>?	NEXNUWgzOzV4NES4Ni=>
SGC7901/VCR-NC	NGf6PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjYUZFKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>?	MXuyN\|U3PDR6Mh?=
SGC7901/VCR-si-SGO1	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnKyTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=>	NVnxXGFLOjN3NkS0PFI>
SGC7901/ADR	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITydWNKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t	MXqyN\|U3PDR6Mh?=
SGC7901/ADR-NC	NFnVW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jZ[2lEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw>	NXztVIhZOjN3NkS0PFI>
SGC7901/ADR-si-SGO1	M3TwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j6bWlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw>	NY[1WHNQOjN3NkS0PFI>
SH-SY5Y	NEfxRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjLSZByOC5yMEGtNVAh\|ryP	MoHqNlQhcA>?		NUi2U5NrUUN3ME2wMlEyO8LzMD6wNVIh\|ryP	Mn7mNlMyOjlyNkW=
SH-SY5Y	NEW2VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXSwMlAxOS1zMDFOwG0>	M3PhNlQ5KGh?		MlXiTWM2OD1yLkC3POKyOC5yMEmg{txO	NWDjeHY1OjNzMkmwOlU>
SH-SY5Y	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u5bVAvODBzLUGwJO69VQ>?	NEjFb\|A4OiCq		NYD4NYt3UUN3ME2wMlA2OcLzMD6wNFgh\|ryP	M3vVcVI{OTJ7ME[1
SH-SY5Y	MlXURZBweHSxc3nzJGF{e2G7	NIHiVFcxNjFizszN	MWiwMVI1KGh?		NH3kOlRqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS\|IwVSCyaHHz[S=>	M2\FSFI{OTJ7ME[1
SH-SY5Y	M3XDRmFxd3C2b4Ppd{BCe3OjeR?=	MX6wMlEh\|ryP	MUKwMVI1KGh?		MWTpcoR2[2W\|IH3peI91cWNiYYLy[ZN1yqB?	NFv2PGIzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]	+ Expand Cell lines: B16 melanoma cell Concentrations: 10 nM Incubation Time: 3 days Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA. (Only for Reference)
Animal Research:^[6]	+ Expand Animal Models: Human rhabdomyosarcoma xenografts Rh12 Formulation: Water solutioin Dosages: 3 mg/kg Administration: A single i.p. administration (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

+ Expand

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Formulation: Water solutioin
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Leurocristine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate

Cited by 21 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vincristine sulfate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate

Cited by 21 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vincristine sulfate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)